BAM
SPRY icon

Belpointe Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Belpointe Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
25,756
-12,689
-33% -$109K 0.01% 1062
2026
Q1 		$309K Buy
38,445
+12,977
+51% +$124K 0.01% 851
2025
Q4 		$297K Buy
25,468
+6,608
+35% +$64.3K 0.01% 828
2025
Q3 		$190K Buy
18,860
+1,537
+9% +$22.1K 0.01% 939
2025
Q2 		$302K Buy
+17,323
New +$250K 0.01% 752

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Belpointe Asset Management's SPRY Position: Q2 2026 in Review

Belpointe Asset Management reduced its ARS Pharmaceuticals (SPRY) stake by 33% in Q2 2026, selling an estimated $109K and leaving 25,756 shares worth $206K. The position accounts for 0.01% of the portfolio, ranked #1062.

Belpointe Asset Management first reported a position in SPRY in Q2 2025 and has held it in 5 quarters since. The position peaked at $309K in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Belpointe Asset Management held 25,756 shares of ARS Pharmaceuticals worth $206K as of Q2 2026.
  • Belpointe Asset Management sold 12,689 ARS Pharmaceuticals shares in Q2 2026, an estimated $109K.
  • ARS Pharmaceuticals made up 0.01% of Belpointe Asset Management's portfolio in Q2 2026, its #1062 holding.
  • Belpointe Asset Management first reported a position in ARS Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Belpointe Asset Management's ARS Pharmaceuticals position peaked at $309K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.